Melanoma, version 4.2014.

Area of Science:

• Oncology
• Dermatology
• Clinical Practice Guidelines

Background:

• Melanoma management requires updated, evidence-based recommendations.
• The National Comprehensive Cancer Network (NCCN) provides guidelines for melanoma care.
• Recent advancements necessitate guideline revisions.

Purpose of the Study:

• To highlight key updates in the NCCN Guidelines for Melanoma.
• To inform clinicians about new treatment options and ongoing controversies.
• To provide current recommendations for melanoma patient management.

Main Methods:

• Review of recent clinical trial data and expert consensus.
• Analysis of evidence supporting systemic therapies and adjuvant treatments.
• Integration of new findings into clinical practice guidelines.

Main Results:

• Dabrafenib and trametinib (monotherapy or combination) are now recommended (category 1) for unresectable metastatic melanoma with BRAF V600 mutations.
• Adjuvant radiation for high-risk stage III melanoma (positive nodes or recurrence) is considered controversial, with a category 2B designation.
• The guidelines reflect ongoing debate on the role of adjuvant radiation post-lymphadenectomy.

Conclusions:

• Updated NCCN guidelines incorporate targeted therapies for specific melanoma mutations.
• The management of high-risk stage III melanoma with adjuvant radiation requires careful consideration due to ongoing controversy.
• These insights guide multidisciplinary decision-making in melanoma treatment.